Navigation überspringen

Neuigkeiten

Haybury

Cover Image

Neuigkeiten

Haybury 
Haybury
Hayburyhat einen Beitrag geschrieben.28. Februar 2019
Immatics, Roche ally to trial Tecentriq with cell therapy https://bit.ly/2U9zMMj

Immatics, Roche ally to trial Tecentriq with cell therapy

Immatics has struck a deal to test its autolog | Immatics has struck a deal to test its autologous cell therapy in combination with Roche’s checkpoint inhibitor Tecentriq. The clinical collaboration clears Immatics to test whether Roche’s antibody boosts the efficacy of its IMA101 in solid tumors.www.fiercebiotech.com
Immatics, Roche ally to trial Tecentriq with cell therapy
Haybury
Hayburyhat einen Beitrag geschrieben.27. Februar 2019
Novartis pays $150M to license Akcea-Ionis cardiac disease drug https://bit.ly/2IFoSg0

Novartis pays $150M to license Akcea-Ionis cardiac disease drug

Novartis has taken up its option to license antisense oligonucleotide TQJ230, triggering a $150 million payout that Akcea Therapeutics will share with Ionis Pharmaceuticals. | Novartis has taken up its option to license antisense oligonucleotide TQJ230, triggering a $150 million payout that Akcea Therapeutics will share with Ionis Pharmaceuticals. The decision sets Novartis up to test the RNA-targeting drug in a phase 3 cardiovascular outcomes trial.www.fiercebiotech.com
Novartis pays $150M to license Akcea-Ionis cardiac disease drug
Haybury
Hayburyhat einen Beitrag geschrieben.20. Februar 2019
Novartis’ AveXis doubles down with $115M manufacturing investment https://bit.ly/2Sc8bZl

Novartis’ AveXis doubles down with $115M manufacturing investment

As an FDA action date quickly approaches for a gene therapy that Novartis snatched up last year, the biotech that is developing the treatment says it needs to more than double the size of | AveXis, which Novartis acquired last year for $8.7 billion, announced it will invest another $60 million and hire another 200 workers for the site it is building in Durham, North Carolina. That is on top of the $55 million it pledged to invest in the plant last year when it first projected hiring 200 employees.www.fiercepharma.com
Novartis’ AveXis doubles down with $115M manufacturing investment
Haybury
Hayburyhat einen Beitrag geschrieben.6. Februar 2019
Merck’s Prevnar challenger nabs FDA ‘breakthrough’ tag. Should Pfizer be worried? https://bit.ly/2GlRng6

Merck’s Prevnar challenger nabs FDA ‘breakthrough’ tag. Should Pfizer be worried?

Merck & Co.’s endeavor to challenge Prevnar 13, the world’s best-selling vaccine, just got a speed-up. But it doesn’t appear to have too much of a lead over rival Pfizer. | Merck & Co.’s endeavor to challenge Prevnar 13, the world’s best-selling vaccine, just got a speed-up. But except for a small head start in phase 3 trials, the blockbuster's would-be rival doesn’t appear to have a big lead over Pfizer, which is developing a 20-strain shot.www.fiercepharma.com
Merck’s Prevnar challenger nabs FDA ‘breakthrough’ tag. Should Pfizer be worried?
Alle Neuigkeiten